论文部分内容阅读
目的对利福喷汀联用链霉素治疗儿童肺结核的临床效果进行观察。方法以我院2010年7月至2012年9月收治的90例儿童肺结核为观察对象,按照随机数字表法分为联合用药组与对照组,联合用药组给予利福喷汀联用链霉素,对照组给予利福平,两组都联合左氧氟沙星和吡嗪酰胺进行治疗。比较两组的临床疗效。结果与对照组相比,联合用药组的转阴率(84.4%)明显高于对照组(75.6%),差异有统计学意义(χ2=10.36,P<0.05);联合用药组肺部病灶的好转率(93.3%)明显高于对照组(80.0%),差异有统计学意义(χ2=8.23,P<0.05)。联合用药组临床疗效优于对照组。与对照组相比,联合用药组的复发率(10.5%)明显低于对照组(23.5%),差异有统计学意义(χ2=4.36,P<0.05)。联合用药组在治疗期间出现的不良反应例数为7例(15.5%),对照组5例(11.1%),两组不良反应比较,差异无统计学意义(χ2=0.13,P>0.05)。结论利福喷汀联用链霉素治疗儿童肺结核临床疗效显著,不良反应少,临床值得推广应用。
Objective To observe the clinical effect of rifapentine combined with streptomycin in the treatment of children’s pulmonary tuberculosis. Methods Totally 90 children with pulmonary tuberculosis admitted from July 2010 to September 2012 in our hospital were divided into the combined group and the control group according to the random number table. The combination group was given rifapentine combined with streptomycin , The control group was given rifampicin, both groups were treated with levofloxacin and pyrazinamide. The clinical efficacy of the two groups was compared. Results Compared with the control group, the negative conversion rate (84.4%) in the combination group was significantly higher than that in the control group (75.6%) (χ2 = 10.36, P <0.05) Improvement rate (93.3%) was significantly higher than the control group (80.0%), the difference was statistically significant (χ2 = 8.23, P <0.05). The clinical efficacy of combination group was better than that of control group. Compared with the control group, the recurrence rate of the combination group (10.5%) was significantly lower than that of the control group (23.5%), the difference was statistically significant (χ2 = 4.36, P <0.05). There were 7 cases (15.5%) of adverse reactions in the combination group and 5 cases (11.1%) in the control group. There was no significant difference in adverse reactions between the two groups (χ2 = 0.13, P> 0.05). Conclusion Rifapentin combined with streptomycin in children with tuberculosis clinical significant effect, fewer adverse reactions, the clinical worthy of promotion and application.